[go: up one dir, main page]

AU2001232340A1 - Novel isoxazole and thiazole compounds and use thereof as drugs - Google Patents

Novel isoxazole and thiazole compounds and use thereof as drugs

Info

Publication number
AU2001232340A1
AU2001232340A1 AU2001232340A AU3234001A AU2001232340A1 AU 2001232340 A1 AU2001232340 A1 AU 2001232340A1 AU 2001232340 A AU2001232340 A AU 2001232340A AU 3234001 A AU3234001 A AU 3234001A AU 2001232340 A1 AU2001232340 A1 AU 2001232340A1
Authority
AU
Australia
Prior art keywords
group
thiazole compounds
atom
drugs
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232340A
Inventor
Rika Nagao
Hideo Ohta
Akihiro Ueno
Tomoko Watanabe
Mikio Yagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Publication of AU2001232340A1 publication Critical patent/AU2001232340A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel isoxazole and thiazole compounds having an excellent lysophosphatidic acid (LPA) receptor antagonistic activity represented by general formula Ä1Ü or salts thereof: <IMAGE> wherein R1 and R2 represents an optionally substituted alkyl group or the like; R3 represents a hydrogen atom or the like; R4 represent a group selected from the group consisting of (I) optionally substituted phenyl, aryl, or heterocycle, (II) substituted or nonsubstituted alkyl, and (III) substituted or nonsubstituted alkenyl, alternatively, R3 and R4 may form a ring structure together with a carbon atom to which they bind; and X represents an oxygen atom or a sulfur atom, provided that, when R3 is a hydrogen atom, R4 represents a group other than methyl, and the use thereof as a medicine.
AU2001232340A 2000-02-18 2001-02-19 Novel isoxazole and thiazole compounds and use thereof as drugs Abandoned AU2001232340A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000041922 2000-02-18
JP2000-41922 2000-02-18
PCT/JP2001/001173 WO2001060819A1 (en) 2000-02-18 2001-02-19 Novel isoxazole and thiazole compounds and use thereof as drugs

Publications (1)

Publication Number Publication Date
AU2001232340A1 true AU2001232340A1 (en) 2001-08-27

Family

ID=18565067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232340A Abandoned AU2001232340A1 (en) 2000-02-18 2001-02-19 Novel isoxazole and thiazole compounds and use thereof as drugs

Country Status (11)

Country Link
US (1) US6964975B2 (en)
EP (1) EP1258484B1 (en)
AT (1) ATE420878T1 (en)
AU (1) AU2001232340A1 (en)
CY (1) CY1110263T1 (en)
DE (1) DE60137405D1 (en)
DK (1) DK1258484T3 (en)
ES (1) ES2320320T3 (en)
PT (1) PT1258484E (en)
TW (1) TWI288136B (en)
WO (1) WO2001060819A1 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7064217B2 (en) 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
JP4396808B2 (en) 2001-02-08 2010-01-13 小野薬品工業株式会社 Urological disease therapeutic agent comprising LPA receptor modulator
JPWO2003007991A1 (en) * 2001-07-17 2004-11-04 小野薬品工業株式会社 Pancreatic secretion regulator comprising LPA receptor modulator
EP1533294A4 (en) * 2002-05-28 2007-07-04 Ono Pharmaceutical Co Beta-alanine derivative and use thereof
EP1550461A1 (en) 2002-06-26 2005-07-06 Ono Pharmaceutical Co., Ltd. Remedy for chronic disease
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
AU2003259296A1 (en) 2002-07-30 2004-02-16 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (en) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Type 1 ryanodine receptor based method
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7524638B1 (en) 2003-06-27 2009-04-28 Osi Pharmaceuticals, Inc. Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease
WO2005012269A1 (en) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. Novel azole compound
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2006088944A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
FR2889190A1 (en) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si New imidazole carboxamides, useful to treat e.g. pathologies associated with the insulin resistance syndrome, are fructose-1,6-biphosphatase inhibitors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
MX2008009579A (en) 2006-01-27 2008-09-25 Univ Virginia Method for treatment of neuropathic pain.
WO2007092638A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
WO2008064320A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010510251A (en) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション Benzocycloheptyl analog having sphingosine = 1-phosphate receptor activity
JP2010510249A (en) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション Sphingosine = 1-tetralin analog having 1-phosphate agonist activity
DE102007047738A1 (en) * 2007-10-05 2009-04-09 Merck Patent Gmbh imidazole derivatives
ES2637805T3 (en) * 2008-05-05 2017-10-17 Sanofi Fused cyclopentanecarboxylic acid derivatives substituted by acylamino and their use as pharmaceuticals
TWI450898B (en) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa Aryl isoxazole compounds with antitumoural activities
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
KR101678255B1 (en) 2009-09-25 2016-11-21 아스텔라스세이야쿠 가부시키가이샤 Substituted amide compound
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
AR079022A1 (en) 2009-11-02 2011-12-21 Sanofi Aventis DERIVATIVES OF CYCLIC CARBOXYL ACID SUBSTITUTED WITH ACILAMINE, ITS USE AS PHARMACEUTICAL PRODUCTS, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD
US20130253019A1 (en) * 2010-06-15 2013-09-26 John Howard Hutchinson Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159635A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
CN105753858B (en) * 2010-07-02 2019-04-30 Aska制药株式会社 Heterocyclic compounds and inhibitors of p27Kip1 decomposition
HUE040397T2 (en) * 2010-12-07 2019-03-28 Amira Pharmaceuticals Inc Polycyclic lpa1 antagonist and uses thereof
WO2012100436A1 (en) * 2011-01-30 2012-08-02 Curegenix Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
CN103596947A (en) * 2011-04-05 2014-02-19 艾米拉医药股份有限公司 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
WO2012162592A1 (en) * 2011-05-25 2012-11-29 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc Lysophosphatidic acid receptor antagonists
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
US20130150426A1 (en) 2011-11-22 2013-06-13 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
WO2013171316A1 (en) * 2012-05-18 2013-11-21 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
KR102189166B1 (en) * 2012-12-28 2020-12-09 우베 고산 가부시키가이샤 Halogen-substituted heterocyclic compound
MX382748B (en) * 2013-03-15 2025-03-13 Epigen Biosciences Inc HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF A DISEASE.
EA038294B1 (en) * 2013-05-24 2021-08-05 Эпиджен Байосайенсиз, Инк. Heterocyclic compounds useful in the treatment of diseases
CN104788343A (en) * 2014-01-16 2015-07-22 同济大学 Ortho-substituted allyl carbamate compound and preparation method thereof
RU2689315C2 (en) * 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Halogen substituted heterocyclic compound salt
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
JP7369125B2 (en) * 2017-12-19 2023-10-25 ブリストル－マイヤーズ スクイブ カンパニー Isoxazole O-bridged carbamoylcyclohexylate as LPA antagonist
CN112041304B (en) 2017-12-19 2025-03-07 百时美施贵宝公司 Isoxazole N-linked carbamoylcyclohexyl acids as LPA antagonists
KR20200100722A (en) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Cyclohexyl acid isoxazole azine as an LPA antagonist
CN112189010A (en) 2017-12-19 2021-01-05 百时美施贵宝公司 Triazole N-linked carbamoylcyclohexanoic acids as LPA antagonists
EP3728242B1 (en) 2017-12-19 2023-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
EP3807254A4 (en) * 2018-06-18 2022-03-23 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
US20230250093A1 (en) * 2020-07-16 2023-08-10 Chiesi Farmaceutici S.P.A. Amido cyclohexane acid derivatives as lpa receptor inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1090795A (en) 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5861359A (en) * 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
AU5328598A (en) 1996-12-18 1998-07-15 Medical Research Council Lysophosphatidic acid acyltransferase gene and its use
SE9904044D0 (en) * 1999-11-09 1999-11-09 Astra Ab Compounds
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use

Also Published As

Publication number Publication date
DE60137405D1 (en) 2009-03-05
CY1110263T1 (en) 2015-01-14
DK1258484T3 (en) 2009-04-20
WO2001060819A1 (en) 2001-08-23
EP1258484B1 (en) 2009-01-14
US6964975B2 (en) 2005-11-15
EP1258484A1 (en) 2002-11-20
ES2320320T3 (en) 2009-05-21
EP1258484A4 (en) 2003-04-23
TWI288136B (en) 2007-10-11
PT1258484E (en) 2009-04-03
US20030114505A1 (en) 2003-06-19
ATE420878T1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
AU2001232340A1 (en) Novel isoxazole and thiazole compounds and use thereof as drugs
IL147651A0 (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
BRPI0213243B8 (en) aromatic heterocyclic compound containing an oxazole, thiazole or imidazole ring, or a pharmaceutically acceptable salt thereof, and pharmaceutical composition
FI943561A0 (en) New compositions of matter
EP1310494A4 (en) PPAR (delta) ACTIVATORS
GB9910577D0 (en) Chemical compounds
SG165361A1 (en) Antituberculous composition comprising oxazole compounds
GB0408399D0 (en) Aryl substituted oxazolidinones with antibacterial activity
DE60239170D1 (en) Bicyclic compounds
ES2005186A6 (en) Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds
EP1357124A4 (en) Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient
ATE137500T1 (en) SUBSTITUTED PYRIDINE SULPHONAMIDE COMPOUNDS, HERBICIDE COMPOSITIONS CONTAINING SAME AND METHOD FOR THE PRODUCTION THEREOF
BR9508676A (en) Carbamolicarboxamide composition processes to prepare compounds and the composition and to control harmful fungi and use compost and compositions
ES2174077T3 (en) ANTI-CHEMICAL HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS.
SE8101703L (en) NEW ISOXAZOLD DERIVATIVES JUST SET FOR THEIR PREPARATION
TW200626007A (en) Material for electroluminescent element and electroluminescent element